Deficiency of FLOT2 is associated with particular changes in PB and BM. (A) Percentage of CD11b⁺ myeloid cells, B220⁺ B cells, CD3⁺ T cells, and Ter119⁺ erythrocytes of total cells in the PB of WT (red) vs Flot2 KO (Flot2) (blue) mice (P = .0204; ANOVA; Tukey test; n = 10-11). (B) Percentage of Lin⁻ c-Kit⁺ Sca1⁺ (LKS) or LKS CD150⁺ CD48^- (LKS SLAM) cells of total leukocytes in PB of WT (red) vs Flot2 KO (blue) mice (P = .0006; ANOVA; Tukey test; n = 3). (C) Percentage of LKS cells of total leukocytes in the PB of WT (red) or Flot2 KO (blue) mice treated with either vehicle or G-CSF (4 µg/dose for 4 consecutive days) (P = .0409 ANOVA; Tukey test; n = 5). (D) Cell cycle analysis of LKS cells, derived from BM of WT or Flot2 KO mice, stained with anti-ki67 and DAPI. The cells are gated on LKS cells (P = .0144; ANOVA; Tukey test; n = 4). (E) Immunofluorescence staining showing the localization of myosin IIa in uropods of WT or Flot2 KO Lin- cells treated with vehicle or CXCL12 (1 ng/µL) for 30 minutes. The same effect was observed after a CXCL12 exposure of 4 hours (data not shown). The images are representative of 3 independent experiments. The scale bar represents 10 µm. (F) Quantification of the percentage of myosin IIa staining in uropods in WT (red) or Flot2 KO (blue) Lin- cells per image as in (E) (P =.0008 [WT]; n.s. [Flot2 KO]; ANOVA; Tukey test; n = 10-15).